直接口服抗凝药逆转治疗危及生命出血的临床指南
该指南由欧洲麻醉学与重症监护学会(ESAIC)制定,系统检索达比加群、利伐沙班、阿哌沙班、艾多沙班四种DOAC在计划至急诊手术场景中的文献,采用GRADE方法评价证据质量,经Delphi流程形成35条推荐和临床实践声明。因缺乏前瞻性随机对照试验,多数证据为非对照观察性研究,证据确定性评为低或极低(GRADE C)。核心推荐包括:DOAC特异性凝血监测可能有助于识别DOAC水平升高的高危患者,不推荐用全局凝血试验排除临床相关DOAC水平;紧急情况下无需等待DOAC水平监测即启动止血治疗;DOAC水平>50 ng/ml可考虑为临床相关,需在紧急或急诊操作前止血;FXa抑制剂下心脏手术前不推荐使用andexanet alfa;DOAC过量无出血时不建议止血干预,而应采取清除DOAC的措施。
要点
- 紧急临床情况下,使用直接逆转剂或非特异性止血剂启动止血治疗不应等待DOAC水平监测结果。
- DOAC水平>50 ng/ml可考虑为临床相关,需在紧急或急诊操作前进行止血治疗。
- DOAC特异性凝血监测可能有助于DOAC水平升高的高危患者;不推荐用全局凝血试验排除临床相关DOAC水平。
- 在FXa抑制剂治疗下接受心脏手术前,不推荐使用andexanet alfa,因其抑制体外循环所需普通肝素。
- DOAC过量但无出血时,不建议止血干预,而应采取清除DOAC的措施。
适用人群与场景
- 服用DOAC(达比加群、利伐沙班、阿哌沙班、艾多沙班)并接受紧急或急诊操作的患者。
- 服用DOAC并发生严重或危及生命出血的患者。
诊断标准与关键阈值
- DOAC水平>50 ng/ml可考虑为临床相关,需在紧急或急诊操作前进行止血治疗。
- DOAC特异性凝血监测可能有助于DOAC水平升高的高危患者;不推荐使用全局凝血试验排除临床相关DOAC水平。
处置流程与药物剂量
- 紧急临床情况下,使用直接逆转剂或非特异性止血剂启动止血治疗不应等待DOAC水平监测。
- 在FXa抑制剂治疗下接受心脏手术前,不推荐使用andexanet alfa,因其抑制体外循环所需的普通肝素。
- DOAC过量但无出血时,不建议止血干预,而应采取清除DOAC的措施。
- 因缺乏临床数据,无法给出使用重组活化凝血因子VII作为非特异性止血剂的推荐。
红旗征与不能漏的情况
- 严重或危及生命出血可能需要紧急止血干预。
- 需要紧急侵入性操作的患者可能需要逆转DOAC。
研究设计与关键结果
- 系统检索比较达比加群、利伐沙班、阿哌沙班、艾多沙班四种药物,场景从计划手术至急诊手术,结局包括死亡率、血肿扩大和血栓栓塞并发症。
- 尚无比较两种活性对照(如直接逆转剂与凝血酶原复合物等非特异性止血剂)的前瞻性随机试验发表,多数发表文献为非对照观察性研究。
- 证据确定性评为低或极低(GRADE C)。
- 共制定35条推荐和临床实践声明;Delphi流程中97.1%的推荐达成强共识(>90%同意),2.9%达成共识(75%至90%同意)。
证据类型、等级与局限
- 证据类型:指南;采用GRADE方法评价证据质量,证据确定性低或极低(GRADE C)。
- 局限:尚无比较两种活性对照的前瞻性随机试验发表,多数文献为非对照观察性研究;缺乏已发表的比较性前瞻性随机研究结果,逆转治疗策略相对于非特异性止血治疗的优越性在多数紧急操作和出血中不明确;因临床数据缺乏,无法给出重组活化凝血因子VII作为非特异性止血剂的推荐;最佳逆转策略尚待未来试验确定。
对床旁实践的改变
- 服用DOAC患者需紧急操作或发生DOAC相关出血时,医生应在启动治疗前评估操作的出血风险和DOAC相关出血的严重程度。
- 紧急情况下不应为等待DOAC水平监测而延迟止血治疗。
- DOAC水平>50 ng/ml可考虑为临床相关,需在紧急或急诊操作前止血。
- FXa抑制剂治疗下心脏手术前不推荐使用andexanet alfa。
- DOAC过量无出血时不建议止血干预,而应采取清除DOAC的措施。
- 不推荐用全局凝血试验排除临床相关DOAC水平。
指南或共识出处
- 指南名称:Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding;发布机构:欧洲麻醉学与重症监护学会(ESAIC);发表于European Journal of Anaesthesiology。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Anticoagulation is essential for the treatment and prevention of thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) over vitamin K antagonists in DOAC-eligible patients. The major complication of anticoagulation is serious or life-threatening haemorrhage, which may necessitate prompt haemostatic intervention. Reversal of DOACs may also be required for patients in need of urgent invasive procedures. This guideline from the European Society of Anaesthesiology and Intensive Care (ESAIC) aims to provide evidence-based recommendations and suggestions on how to manage patients on DOACs undergoing urgent or emergency procedures including the treatment of DOAC-induced bleeding.
DESIGN: A systematic literature search was performed, examining four drug comparators (dabigatran, rivaroxaban, apixaban, edoxaban) and clinical scenarios ranging from planned to emergency surgery with the outcomes of mortality, haematoma growth and thromboembolic complications. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology was used to assess the methodological quality of the included studies. Consensus on the wording of the recommendations was achieved by a Delphi process.
RESULTS: So far, no results from prospective randomised trials comparing two active comparators (e.g. a direct reversal agent and an unspecific haemostatic agent such as prothrombin complex concentrate: PCC) have been published yet and the majority of publications were uncontrolled and observational studies. Thus, the certainty of evidence was assessed to be either low or very low (GRADE C). Thirty-five recommendations and clinical practice statements were developed. During the Delphi process, strong consensus (>90% agreement) was achieved in 97.1% of recommendations and consensus (75 to 90% agreement) in 2.9%.
DISCUSSION: DOAC-specific coagulation monitoring may help in patients at risk for elevated DOAC levels, whereas global coagulation tests are not recommended to exclude clinically relevant DOAC levels. In urgent clinical situations, haemostatic treatment using either the direct reversal or nonspecific haemostatic agents should be started without waiting for DOAC level monitoring. DOAC levels above 50 ng ml-1 may be considered clinically relevant necessitating haemostatic treatment before urgent or emergency procedures. Before cardiac surgery under activated factor Xa (FXa) inhibitors, the use of andexanet alfa is not recommended because of inhibition of unfractionated heparin, which is needed for extracorporeal circulation. In the situation of DOAC overdose without bleeding, no haemostatic intervention is suggested, instead measures to eliminate the DOACs should be taken. Due to the lack of published results from comparative prospective, randomised studies, the superiority of reversal treatment strategy vs. a nonspecific haemostatic treatment is unclear for most urgent and emergency procedures and bleeding. Due to the paucity of clinical data, no recommendations for the use of recombinant activated factor VII as a nonspecific haemostatic agent can be given.
CONCLUSION: In the clinical scenarios of DOAC intake before urgent procedures and DOAC-induced bleeding, practitioners should evaluate the risk of bleeding of the procedure and the severity of the DOAC-induced bleeding before initiating treatment. Optimal reversal strategy remains to be determined in future trials for most clinical settings.
参考来源
- Grottke O, Afshari A, Ahmed A, et al. Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding. Eur J Anaesthesiol. 2024. PMID: 38567679. doi:10.1097/EJA.0000000000001968
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。